Initiation of centrosome duplication and DNA replication is coupled, which is primarily achieved by the late G1 phase-specific activation of cyclin-dependent kinase 2 (CDK2)-cyclin E, which triggers both centrosome duplication and DNA replication. Uncoupling of these two events contributes to overduplication of centrosomes, resulting in the presence of more than two centrosomes (centrosome amplification). Centrosome amplification, which is frequently observed in cancers, contributes to tumor development through destabilizing genomes. Nucleophosmin (NPM/B23) is one of the phosphorylation targets of CDK2-cyclin E for the initiation of centrosome duplication. It has been found that NPM/B23 phosphorylated on Thr199 by CDK2-cyclin E acquires a high binding affinity to ROCK II kinase. The Thr199-phosphorylated NPM/B23 physically interacts with and super-activates the centrosomally localized ROCK II, which is a critical event for centrosomes to initiate duplication. Here, we provide direct evidence for the activation of ROCK II as a primary and sufficient downstream event of CDK2-cyclin E for the initiation of centrosome duplication and for the induction of centrosome amplification.
Introduction
The centrosome is a small non-membranous organelle, and normally found at the periphery of the nucleus. The function of the centrosome is to nucleate and anchor microtubules, and thus the centrosome plays a vital role in the formation of proper mitotic spindles. The centrosome consists of a pair of centrioles (duplication units of the centrosome) and proteinaceous matrix surrounding the centrioles (pericentriolar material). The presence of two centrosomes ensures the formation of bipolar mitotic spindles, an essential event for accurate chromosome segregation during cytokinesis (reviewed by Doxsey (2001) and Fukasawa (2005) ). As each daughter cell receives only one centrosome upon cytokinesis, centrosome must duplicate once in each cell cycle (reviewed by Hinchcliffe and Sluder (2002) ). Uncontrolled activation of the positive regulators as well as loss/inactivation of the negative regulators of centrosome duplication leads to overduplication of centrosomes, resulting in the generation of more than two centrosomes (centrosome amplification) (reviewed by Fukasawa (2007) ). Centrosome amplification interferes with the formation of bipolar spindles, leading to a high frequency of chromosome segregation errors. Thus, centrosome amplification, which is frequently found in various types of tumors, accelerates tumor progression by simultaneously introducing multiple genetic alterations (reviewed by D' Assoro et al. (2002) and Fukasawa (2007) ).
Cyclin-dependent kinase (CDK) 2-cyclin E complex, a known initiator of DNA replication (reviewed by Morgan (1997) ), also acts as an initiator of centrosome duplication (Hinchcliffe et al., 1999; Lacey et al., 1999; Matsumoto et al., 1999) . Thus, initiation of centrosome duplication and DNA replication is at least in part coupled by the temporal activation of CDK2-cyclin E in late G1. Coupling of these two events is essential for centrosomes to duplicate once in each cell cycle, and uncoupling of these two events lays a favorable ground for centrosomes to overduplicate. Several potential centrosomal targets of CDK2-cyclin E has been identified, including nucleophosmin (NPM/B23), Mps1kinase and centrosomal protein CP110 (Okuda et al., 2000; Fisk and Winey, 2001; Chen et al., 2002) . However, beyond the potential involvement of these proteins in the initiation of centrosome duplication, the molecular events downstream of CDK2-cyclin E responsible for the control of the initiation of centrosome duplication had not been fully understood. It has recently been shown that NPM/B23 phosphorylated by CDK2/cyclin E acquires a high binding affinity to ROCK II kinase (also known as Rho-associated kinase), resulting in the physical association between NPM/B23 and centrosomally localized ROCK II (Ma et al., 2006) . ROCK II has an N-terminal kinase domain and C-terminal autoinhibitory domain. The autoinhibitory domain folds back to interact with the N-terminal kinase domain, resulting in the inhibition of the kinase activity. Although Rho small GTPase binds to the Rhobinding domain of ROCK II located in the C-terminus, releasing the kinase domain, Rho binding only results in 1.5-to 2-fold increase in the kinase activity of ROCK II (Leung et al., 1996; Matsui et al., 1996; Nakagawa et al., 1996) . Thus, further upregulation of the kinase activity may be a critical event for ROCK II to properly function in certain biological processes. The NPM/B23 binding further increases the kinase activity of ROCK II (5-to 10-fold), and this super-activation of ROCK II is an essential event for the initiation of centrosome duplication (Ma et al., 2006) . In this study, we examined the importance of ROCK II as a target of CDK2-cyclin E for the initiation of centrosome duplication and induction of centrosome amplification through testing whether exogenously introduced active ROCK II rescues the inability of initiating centrosome duplication and of inducing centrosome amplification in the cells depleted for the CDK2 activity. We found that the ROCK II activation is a sufficient downstream event of CDK2-cyclin E for initiating centrosome duplication and inducing centrosome amplification.
Results
Overexpression of constitutively active ROCK II allows centrosome duplication in cells expressing dominant-negative CDK2 Although unphosphorylated NPM/B23 is able to interact with ROCK II, acquisition of a higher binding affinity to ROCK II by CDK2-mediated phosphorylation on Thr199 is critical for the NPM/B23-ROCK II interaction in vivo where the protein (especially ROCK II) concentration is limited. Thus, when ROCK II is overexpressed, the requirement of the phosphorylation of NPM/B23 by CDK2-cyclin E for the in vivo ROCK II-NPM/B23 interaction can be at least partially alleviated (Ma et al., 2006) . If super-activation of ROCK II by binding of NPM/B23 phosphorylated by CDK2-cyclin E is a primary target of CDK2-cyclin E to initiate centrosome duplication, overexpression of constitutively active ROCK II mutant that lacks the C-terminal autoinhibitory domain (commonly known as a CAT mutant; Amano et al., 1999) should be able to drive centrosome duplication in cells whose CDK2 is functionally inhibited. To test this hypothesis, primary mouse skin fibroblasts (MSFs) and embryonic fibroblasts (MEFs) immortalized by knocking out p53 were serum-starved, and co-transfected with green fluorescent protein (GFP)-tagged CAT mutant and hemagglutinin (HA)-tagged dominant-negative (DN) CDK2. Immunoblot analysis showed that the similar levels of DN-CDK2 as well as GFP-CAT were expressed among the transfected cells (Figures 1a and c ). The transfected cells were then serum-stimulated in the presence of bromodeoxyuridine (BrdU), and the rates of S-phase entry and centrosome duplication were determined (Figures 1b  and d) . In both vector-transfected control MSFs and p53 À/À MEFs, the rate of initiation of centrosome duplication paralleled with that of BrdU incorporation, indicating the coordinated initiation of centrosome duplication and DNA replication. Ectopic expression of the CAT mutant alone resulted in slight increases in the rates of centrosome duplication compared with the control cells, which was more recognizable in p53
MEFs than in MSFs. As expected, expression of DN CDK2 resulted in the failure to initiate both centrosome duplication and DNA replication in both MSFs and p53 À/À MEFs. However, when the CAT mutant was co-expressed, both MSFs and p53 À/À MEFs regained the abilities to initiate centrosome duplication. Thus, overexpression of constitutively active ROCK II can by-pass the requirement of the CDK2 activity for the initiation of centrosome duplication in both pre-crisis and immortalized cells. Interestingly, expression of the CAT mutant partially rescued the initiation of DNA replication in both MSFs and p53 À/À MEFs whose CDK2 was functionally inhibited, which is unexpected, as the involvement of ROCK II in the initiation of DNA replication has not been reported previously.
To corroborate the above findings, we tested the ability of ROCK II to by-pass the requirement of the CDK2 activity by the centrosome re-duplication assay. This assay system takes advantage of the observation that in the cells permissive for centrosome duplication (that is, cells lacking functional p53; Tarapore et al., 2001) arrested by exposure to DNA synthesis inhibitors such as aphidicolin (Aph), centrosomes continue to re-duplicate without DNA synthesis, resulting in the generation of more than two centrosomes (centrosome amplification) (Balczon et al., 1995) . The centrosome re-duplication assay also simulates centrosome amplification that occurs frequently in cancer cells (Fukasawa, 2007) . MEFs derived from p53-deficient mice prearrested with Aph were transfected with GFP-CAT together with HA-DN CDK2. HA-tagged wild-type (WT) CDK2 and an HA-vector were transfected as positive and negative controls, respectively. The transfected cells were further incubated in the presence of Aph for 48 h. The similar levels of the CAT mutant as well as WT and DN CDK2 were expressed ( Figure 2a ). As reported previously (Ma et al., 2006) , expression of the CAT mutant alone resulted in a significant increase in the frequency of centrosome amplification (480%) (Figure 2b , column 2) compared with the control cells (B60%) (column 1). Transfection of WT CDK2 had little effect on the frequency of centrosome amplification (Figure 2b , column 3), which is likely because of the limited amounts of cyclin E available in cells, and the majority of ectopically expressed CDK2 remain inactive. In contrast, expression of DN CDK2 almost completely inhibited centrosome re-duplication ( Figure 2b , column 5): the frequency of B30% is equivalent to that occurring during the pre-arresting period before transfection. Importantly, when the CAT mutant was co-transfected with DN CDK2, centrosomes re-duplicated as efficiently as the cells transfected with the CAT mutant alone (Figure 2b , column 6 vs column 2). Representative immunostaining images are shown in Figure 2c . These results show that overexpression of constitutively active ROCK II by-passes the requirement of the CDK2 activity for the induction of centrosome amplification in cells arrested in a centrosome duplication permissive stage.
Overexpression of constitutively active ROCK II induces centrosome amplification in cells depleted for both cyclin E and cyclin A as well as in cells silenced for CDK2 expression We have previously shown that as long as cyclin E is present, cyclin A does not participate in the control of centrosome duplication, but in the absence of cyclin E (that is, cells derived from cyclin E À/À mice), cyclin A functionally replaces cyclin E to activate CDK2 to trigger the initiation of centrosome duplication. Thus, depletion of both cyclin E and cyclin A abolishes the intracellular CDK2 activity, leading to inability to initiate centrosome duplication (Hanashiro et al., 2008) . We used this finding as an experimental system to further test ROCK II as a key and sufficient downstream effector of CDK2 to initiate centrosome duplication. MEFs derived from mice deficient for both cyclin E1 and cyclin E2 isoforms, which were stably transfected with DN p53 (Geng et al., 2003; Hanashiro et al., 2008) , were pre-arrested with Aph, and cotransfected with either GFP-vector or GFP-CAT and either small interfering RNA (siRNA) sequence specific for cyclin A or the control siRNA sequence. Cells were further incubated in the presence of Aph for 48 h. After confirming the successful silencing of cyclin A expression and expression of the CAT mutant Figure 1 Expression of constitutively active ROCK II by-passes the requirement of CDK2 for the initiation of centrosome duplication during the cell cycle. Primary MSFs derived from the abdominal skins of 8-week-old C57L mice and MEFs derived from p53 À/À mice were first serum-starved, and co-transfected with HA-tagged DN CDK2 with GFP-tagged CAT mutant. Lysates prepared from the transfected cells were subjected to immunoblot analysis using anti-HA and anti-GFP antibodies (MSFs in (a) and MEFs in (c)). As a loading control, either anti-a-tubulin or anti-b-actin antibody was used. The transfected cells were serum-stimulated in the presence of BrdU, and at every 5 h for a total of 30 h, cells were examined for centrosome duplication by immunostaining g-tubulin as well as centrin and for DNA replication by immunostaining incorporated BrdU, and the results are shown in the graphs (MSFs in (b) and MEFs in (d)). As some cells contain more than two centrosomes, which interferes with the accurate assessment of the frequency of centrosome duplication, only cells with either one or two centrosomes were examined, and the results are shown as number of cells with two centrosomes/total number of cells with one and two centrosomes. (Figure 3a ), the frequencies of centrosome amplification were determined ( Figure 3b ). As expected, introduction of the CAT mutant alone resulted in an increase in the frequency of centrosome amplification (column 2, 480%) compared with the control cells (column 1, B60%). As described previously (Hanashiro et al., 2008) , cyclin E À/À cells silenced for cyclin A expression failed to re-duplicate centrosomes (column 3, B30% of centrosome amplification frequency, which is equivalent to that occurring during the pre-arresting period). However, co-expression of the CAT mutant restored the ability to undergo centrosome re-duplication (column 4), showing that overexpression of the active ROCK II can by-pass the requirement of the CDK2 activity for centrosome duplication/centrosome amplification.
We also tested the effect of the introduction of the CAT mutant in cells silenced for CDK2 expression. MEFs were pre-arrested with Aph, and co-transfected with either GFP-vector or GFP-CAT and either siRNA sequence specific for CDK2 or the control siRNA sequence. Cells were further incubated in the presence of Aph for 48 h. CDK2 was successfully silenced by the expression of CDK2 siRNA (Figure 3c , top panel), and similar levels of GFP-CAT were expressed (middle panel). We then examined the frequencies of centrosome amplification (Figure 3d ). Similarly to the above results for the cells depleted for both cyclin A and E, cells silenced for CDK2 expression failed to re-duplicate centrosomes (column 3), whereas co-expression of the CAT mutant restored the ability to undergo centrosome reduplication (column 4), further showing that the activation of ROCK II is a sufficient downstream event of CDK2 for centrosome duplication/centrosome amplification. À/À MEFs were pre-arrested with Aph for 24 h, and co-transfected with either HA-tagged WT CDK2 or DN CDK2 together with GFP-tagged CAT mutant. Lysates prepared from the transfected cells were subjected to immunoblot analysis using anti-HA and anti-GFP antibodies. As a loading control, anti-a-tubulin antibody was used. (b) The transfected cells were further incubated for 48 h in the presence of Aph, and immunostained with anti-GFP and anti-g-tubulin antibodies, followed by counterstaining for DNA with 4 0 , 6-diamidino-2-phenylindole. The frequency of cells with amplified centrosomes (X3 centrosomes) was then determined, and shown in the graph (b) as the average±standard error from three experiments (**Po0.01). The representative immunostaining images are shown in (c). Right panels of each set show the magnified images of the indicated areas for g-tubulin immunostaining, and the arrowheads point to centrosomes. Scale bar: 10 mm.
Centrosomal localization and NPM/B23 binding are required for the constitutively activated ROCK II mutant to initiate centrosome duplication in the absence of CDK2 activity Although unphosphorylated NPM/B23 can bind to ROCK II in vitro, ROCK II-NPM/B23 interaction in vivo heavily depends on the CDK2-mediated phosphorylation of NPM/B23 owing to a limited intracellular concentration of ROCK II. Thus, only when ROCK II is overexpressed, interaction between ROCK II and unphosphorylated NPM/B23 can be detected (Ma et al., 2006) . To test whether the constitutively active ROCK II expressed at a high level in cells still requires interaction with NPM/B23 to drive centrosome duplication, we analyzed the ability of the CAT mutant lacking the NPM/B23-binding domain, which has been mapped to a.a. 373-420 (CATDNPM). In parallel, we also analyzed the CAT mutant lacking the centrosomelocalization domain (a.a. 457-553) (CATDcen) to test whether the centrosomal localization is still important for overexpressed ROCK II to drive centrosome duplication. Cyclin E À/À cells pre-arrested with Aph were co-transfected with GFP-CAT, -CATDNPM or -CATDcen and either cyclin A siRNA or control siRNA sequence, and were further incubated in the presence of Aph for 48 h. The comparable levels of the transfected proteins were expressed ( Figure 4A, top panel) . To evaluate whether the CATDNPM and CATDcen mutants retain the kinase activities in vivo, we probed the cell lysates prepared from the transfected cells with antiphospho-Ser19 MLC antibody ( Figure 4A , third panel) and anti-pan MLC2 antibody ( Figure 4A, fourth panel) . À/À MEFs were pre-arrested by Aph for 24 h, and co-transfected with either GFP-CAT or GFP-vector control together with either siRNA sequence specific for CDK2 or control siRNA sequence. Lysates prepared from the transfected cells were subjected to immunoblot analysis using anti-CDK2 (top panel) and anti-GFP antibodies (second panel). As a loading control, anti-b-actin antibody was used (bottom panel). (d) The transfected cells in (c) were further incubated for 48 h in the presence of Aph, and the frequency of cells with amplified centrosomes was determined. The results are shown in the graph as the average ± standard error from three experiments (*Po0.05; **Po0.01).
ROCK II in centrosome duplication and amplification K Hanashiro et al
ROCK II phosphorylates MLC2 at Ser19, and Ser19 phosphorylation of MLC2 is known to serve as an indicator of the in vivo ROCK II activity Totsukawa et al., 2000) , although the increase in the levels of phospho-Ser19 MLC2 may also be attributed to the inhibition of MLC phosphatase by ROCK II Feng et al., 1999) . The increased MLC2 phosphorylation was detected in the cells transfected with GFP-CAT as shown previously (Ma et al., 2006) . Similar levels of MLC2 phosphorylation were detected in cells transfected with the CATDNPM as well as CATDcen mutants, showing ROCK II in centrosome duplication and amplification K Hanashiro et al that these mutants retain full kinase activities in vivo (Figures 4Aa and b) . With respect to their centrosome localization activities, GFP-CAT was found at centrosomes ( Figure 4B , panels d-f), whereas GFP-CATDcen was not detected at centrosomes (panels g-i). The CATDNPM mutant was found at centrosomes in a similar manner with GFP-CAT (panels j-l), showing that the CATDNPM mutant retains the centrosome localization activity. We then tested the transfected cells by the centrosome re-duplication assay ( Figure 4C ). As reported previously (Ma et al., 2006) , the CATDcen mutant failed to promote centrosome re-duplication, indicating that the centrosome localization is critical for ROCK II to drive centrosome duplication. Importantly, the CATDNPM mutant could no longer induce centrosome re-duplication, indicating that physical association between NPM/B23 and ROCK II is still required for the overexpressed ROCK II to drive centrosome duplication and to promote centrosome amplification in the cells depleted for the CDK2 activity.
Importance of the physical interaction between ROCK II and NPM/B23 was to by-pass the requirement of the CDK2 activity to induce centrosome amplification It has recently been shown that morgana/CHORDcontaining protein (chp-1), a stress protein (Wu et al., 2005) , suppress the physical interaction between ROCK II and NPM/B23, although directly binding to ROCK II. Thus, depletion of morgana results in the promotion of the ROCK II-NPM/B23 interaction, whereas overexpression of morgana suppresses the physical association between ROCK II and NPM/B23 (Ferretti et al., 2010) . To further investigate the importance of the ROCK II-NPM/B23 interaction in the promotion of centrosome amplification, we tested the effects of overexpression as well as depletion of morgana on the frequency of centrosome amplification in cells depleted for both cyclin A and E. We first co-transfected FLAG-tagged morgana and GFP-CAT to the cyclin E À/À MEFs, in which cyclin A expression was silenced by siRNA. After confirming the successful overexpression of morgana (Figure 5a) , the transfected cells were subjected to the centrosome amplification assay. As shown in Figure 3b , overexpression of the CAT mutant allowed centrosome amplification in the absence of both cyclins A and E ( Figure 5b , column 2). However, co-expression of morgana resulted in a significant reduction in the frequency of centrosome amplification (Figure 5b , column 4). As overexpression of morgana suppresses the ROCK II-NPM/B23 interaction, this result supports that the ROCK II-NPM/B23 interaction is important for the ROCK II-mediated promotion of centrosome amplification. MEFs were transiently transfected with either a cyclin A siRNA or a control siRNA sequence along with a plasmid containing puromycin resistance gene (15:1 molar ratio). The cells selected in the media containing puromycin were treated with Aph overnight, and transfected with either FLAG-morgana or a control FLAG-vector along with either GFP-CAT or a control GFP-vector. The lysates prepared from the transfected cells were subjected to immunoblot analysis (a) with anti-FLAG (top panel), anti-morgana (second panel) and anti-GFP antibodies (third panel). As a loading control, anti-b-actin antibody was used (bottom panel). The transfected cells were further incubated for 48 h in the presence of Aph, and the frequency of cells with amplified centrosomes was determined. The results are shown in the graph as the average±standard error from three experiments (*Po0.05; **Po0.01) (b). Cyclin E À/À MEFs silenced for cyclin A expression were treated with Aph overnight, and transfected with either morgana siRNA or control siRNA sequence along with either GFP-CAT or a control GFP vector. The lysates prepared from the transfected cells were subjected to immunoblot analysis with anti-morgana antibody (top panel) and anti-b-actin antibody (loading control, bottom panel) (c). The transfected cells were further incubated for 48 h in the presence of Aph, and the frequency of cells with amplified centrosomes was determined. The results are shown in the graph as the average±standard error from three experiments (**Po0.01) (d).
Depletion of morgana has been shown to promote the ROCK II-NPM/B23 interaction (Ferretti et al., 2010) . As ROCK II can interact with NPM/B23 that is not phosphorylated on Thr199, although less effectively than Thr199-phosphorylated NPM/B23, it is possible that promotion of the ROCK II-NPM/B23 interaction by depletion of morgana alone may be sufficient to by-pass the requirement of the CDK2 activity for the induction of centrosome amplification. To test this hypothesis, cyclin E À/À cells silenced for cyclin A expression were transfected with the siRNA sequence specific for morgana. As a positive control, GFP-CAT was co-transfected. Expression of morgana was successfully silenced to B10% of the endogenous level (Figure 5c ). The transfected cells were then subjected to the centrosome amplification assay (Figure 5d ). As we hypothesized, depletion of morgana alone was found to be sufficient to induce centrosome amplification in the absence of cyclins A and E (Figure 5d , column 3), further supporting the critical role of the physical interaction of ROCK II and NPM/B23 in the promotion of centrosome amplification.
Discussion
Involvement of ROCK II in the regulation of centrosome duplication was initially speculated from the observations that ROCK II localizes to centrosomes and physically interacts with NPM/B23, which is one of the targets of CDK2 for the initiation of centrosome duplication (Ma et al., 2006) . Further studies revealed the critical role of ROCK II in the initiation of centrosome duplication: inhibition or depletion of ROCK II results in the suppression of centrosome duplication, whereas overexpression of constitutively active form of ROCK II leads to the promotion of centrosome duplication (Ma et al., 2006) . Moreover, physical interaction with NPM/B23 is important for ROCK II to control centrosome duplication. ROCK II is primed for the activation by Rho-GTP binding to the C-terminal autoinhibitory region. Although Rho binding is essential for the activation of ROCK II, the Rho binding alone results in only a minimal activation of ROCK II (1.5-to 2-fold over the unbound ROCK II), and further activation (that is, NPM/B23-binding results in a 5-to 10-fold increase) is expected for ROCK II to function in certain biological events. In this study, we provided direct evidence of ROCK II activation as a sufficient downstream event of CDK2-cyclin E for the initiation of centrosome duplication in cycling cells and induction of centrosome amplification in cell cyclearrested cells. CDK2-cyclin E phosphorylated NPM/ B23 on Thr199 (Okuda et al., 2000; Tokuyama et al., 2001) , and this phosphorylation renders NPM/B23 a high binding affinity to ROCK II, enabling the complex formation between ROCK II and NPM/B23 in vivo (Ma et al., 2006) . Owing to the critical role of CDK2 for centrosome duplication and amplification, functional inhibition of CDK2 by expression of the DN mutant, depletion of both cyclin E and cyclin A, and siRNA-mediated silencing of CDK2 expression all results in failure to initiate centrosome duplication in cycling cells and to induce centrosome amplification in arrested cells. However, exogenously introduced constitutively active ROCK II allows centrosome duplication as well as centrosome amplification in those cells, showing that activation of ROCK II is a sufficient downstream event of CDK2 for centrosome duplication/amplification. We further found that overexpression of the ROCK II mutant defective for NPM/B23 binding failed to by-pass the requirement of the CDK2 activity to initiate centrosome duplication and to induce centrosome amplification. Thus, physical association with NPM/B23 is still required for ROCK II to initiate centrosome duplication and induce centrosome amplification.
We have previously shown that purified ROCK II and NPM/B23 readily form a complex in vitro without CDK2-mediated phosphorylation of NPM/B23 on Thr199. However, because of a limited intracellular concentration of ROCK II, the physical interaction between ROCK II and NPM/B23 in vivo requires the NPM/B23's acquisition of a high binding affinity to ROCK II by Thr199 phosphorylation, and expression of ROCK II in excess gets around the requirement of the NPM/B23 phosphorylation by CDK2-cyclin E for the ROCK II-NPM/B23 interaction in vivo (Ma et al., 2006) . Thus, in the cells, in which CDK2 is either inhibited or depleted, and consequentially there are minimal amounts of Thr199-phosphorylated NPM/B23, the presence of a high level of ROCK II allows the complex formation between ROCK II and unphosphorylated NPM/B23. In support of this prediction, we found that silencing of morgana/cph-1 expression alone was found to be able to induce centrosome amplification in the absence of both cyclin A and E. Morgana/cph-1 is a stress protein found to inhibit ROCK II-NPM/B23 interaction by directly binding to ROCK II, and thus depletion of morgana/chp-1 promotes the ROCK II-NPM/B23 interaction (Ferretti et al., 2010) . Downregulation of morgana/chp-1 promotes the physical interaction between ROCK II and unphosphorylated NPM/B23, leading to an increased ROCK II kinase activity and induction of centrosome amplification (Ferretti et al., 2010) .
The major question remained to be addressed is the role of NPM/B23 binding in the activity of ROCK II to promote centrosome duplication/centrosome amplification. Although it is likely that super-activation of the ROCK II kinase activity is an important role of the NPM/B23 binding as the previous studies have suggested (Ma et al., 2006) , it is also possible that the NPM/B23 binding may influence the target specificity of ROCK II: acquisition of such specificities may be necessary for ROCK II to target the protein(s) that control centrosome duplication. At present, it is difficult to test this possibility, but upon identification of the ROCK II phosphorylation target(s) for centrosome duplication/amplification, such a possibility can be tested. On the basis of the observation that ROCK II needs to localize to centrosomes to control centrosome duplication (Ma et al., 2006;  this study), the phosphorylation target(s) of ROCK II are likely the centrosomelocalizing proteins.
ROCK II has been shown to be upregulated in various cancers (Kamai et al., 2003 (Kamai et al., , 2004 Wong et al., 2009) . Similarly, overexpression/overactivation of Rho proteins, which potentially leads to an increased concentration of the active ROCK II, is also commonly found in cancers (reviewed by Sahai and Marshall (2002) and Ridley (2004) ). Upregulation of ROCK II leads to the ROCK II-NPM/B23 interaction, and consequentially induction of centrosome amplification. In addition, it has been shown that morgana þ /À cells and mice display an increased susceptibility to neoplastic transformation, and morgana is underexpressed in human cancers at a high frequency (Ferretti et al., 2010) . These observations all implicate the aberrant ROCK II-NPM/B23 interaction and consequential amplification of centrosomes in carcinogenesis, which points to the importance of examination of the upstream events (that is, activation of Rho proteins, activation of growth factor and hormone receptors, and so on) as well as the downstream events of ROCK II-NPM/B23 in the initiation of centrosome duplication and induction of centrosome amplification.
Materials and methods

Cells and transfection
) MEFs that stably express DNp53 as well as MEFs derived from p53 À/À mice were maintained in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum, penicillin (100 U/ml) and streptomycin (100 mg/ml) in an atmosphere containing 10% CO 2 at 37 1C. Cells were transfected using Fugene HD (Roche, Mannheim, Germany).
Plasmids
For the expression of the plasmid-based siRNA, we used a pSUPER vector system (OligoEngine, Seattle, WA, USA). The cyclin A sequence corresponding to its cDNA 389-407 (5 0 -AACCACTGACACCTCTTGA-3 0 ) was used as the siR-NA sequence (pSUPER-Cyclin A). For CDK2, the sequence corresponding to its cDNA 169-187 (5 0 -GAACTTAATCACC CTAATA-3 0 ) was used. For morgana, the sequence 5 0 -GAAG AAGACAGUGAUGAAA-3 0 (Ferretti et al., 2010) was used. For a control, a randomized sequence was inserted into the vector (pSUPER-vec).
Antibodies
The primary antibodies used in this study were as follows: anti-HA (12CA5; Roche), anti-GFP (7.1/13.1; Roche), anti-cyclin E (sc-481; Santa Cruz Biotechnology, Santa Cruz, CA, USA), anti-cyclin A (sc-596; Santa Cruz), anti-CDK2 (D-12; Santa Cruz), anti-MLC2 (sc-15370; Santa Cruz), anti-phosphoSer19-MLC2 (3671S; Cell Signaling, Danvers, MA, USA), anti-morgana antibody (Ferretti et al., 2010) , anti-g-tubulin (TU-30; Santa Cruz), anti-a-tubulin (DM1A; Sigma, St Louis, MO, USA), anti-b-tubulin (TUB2.1; Sigma) and anti-b-actin (AC-74; Sigma) antibodies. Anti-g-tubulin polyclonal antibody was produced in our laboratory.
Immunoblot analysis
Cells were lysed in lysis buffer (1% SDS, 1% NP-40, 50 mM Tris (pH 8.0), 150 mM NaCl, 4 mM Pefabloc SC, 2 mg/ml leupeptin, 2 mg/ml aprotinin). The lysates were briefly sonicated, boiled for 5 min and cleared by centrifugation at 20 000 g at 4 1C for 10 min. The lysates were denatured at 95 1C for 5 min in sample buffer (2% SDS, 10% glycerol, 60 mM Tris (pH 6.8), 5% b-mercaptoethanol, 0.01% bromophenol blue), resolved by SDS-polyacrylamide gel electrophoresis and transferred to Immobilon-P sheets (Millipore Corp., Bedford, MA, USA). The blots were incubated in blocking buffer (5% (w/v) non-fat dry milk in Tris-buffered saline þ 0.2% Tween 20) for 1 h at room temperature, and then incubated with primary antibody for 16 h at 4 1C, rinsed in Tris-buffered saline þ 0.2% Tween 20 and incubated with horseradish peroxidase-conjugated secondary antibody for 1 h at room temperature. The blots were rinsed in Tris-buffered saline þ 0.2% Tween 20, and the antibody-antigen complex was visualized by enhanced chemiluminescence (Pierce Biotechnology, Rockford, IL, USA).
Indirect immunofluorescence
Cells were washed in phosphate-buffered saline, and fixed with 10% formalin/1% methanol for 20 min at room temperature. The cells were incubated with 10% normal goat serum in phosphate-buffered saline for 1 h at room temperature, and then probed with primary antibodies for 2 h; antibody-antigen complexes were detected with either Alexa Fluor 488-or Alexa Fluor 594-conjugated goat antibody (Molecular Probes, Eugene, OR, USA). The cells were also counterstained for DNA with 4 0 , 6-diamidino-2-phenylindole. For the BrdU-incorporation assay, serum-starved cells were serumstimulated in the presence of BrdU using the BrdU labeling kit (Roche, Indianapolis, IN, USA). Cells were fixed in 70% ethanol in 50 mM glycine (pH 2.0) for 20 min at À20 1C, followed by incubation with anti-BrdU antibody for 30 min, followed by incubation with fluorescein-conjugated secondary antibody for 30 min. For analyzing the centrosomal localization of introduced GFP-ROCK II, cells were briefly extracted (B15 s) with extraction buffer (0.75% Triton X-100, 5 mM Pipes, 2 mM ethylene glycol-bis(beta-aminoethylether)-N,N,N 0 ,N 0 -tetraacetate (pH 6.7)). Cells were washed in phosphate-buffered saline, and fixed with cold methanol.
Statistical analysis
The data were analyzed by one-way analysis of variance, followed by Scheffe's F test. Difference with Po0.05 was considered as significant.
